Cytokinetics CYTK Current ratio

Current ratio at other companies

Bristol-Myers SquibbBMY

1.5×+0.3×

Eli LillyLLY

1.4×+0.1×

Merck & Co.MRK

1.3×-0.1×

Lexicon PharmaceuticalsLXRX

13.4×+9.2×

Edgewise Therapeutics, Inc.EWTX

22.6×+1.6×

Capricor TherapeuticsCAPR

8.4×+1.9×

FAQ

What is Cytokinetics's current ratio?

Cytokinetics (CYTK) reported current ratio of 6.7× in Q2 2026.

How has Cytokinetics's current ratio changed year-over-year?

Cytokinetics's current ratio decreased by 1.5% year-over-year, from 6.8× to 6.7×.

What is the long-term trend for Cytokinetics's current ratio?

Over 5 years (2020 to 2025), Cytokinetics's current ratio has grown at a -21.5% compound annual growth rate (CAGR), from 15.2× to 4.5×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.